DXCM
DexCom, Inc.
Healthcare · Medical Devices · United States · Stock
Score Breakdown
Scored for Aggressive Growth profile
Sub-scores are 0–20 each; Model Score is weighted by your selected investment goal. How it works →
Why Ranked Here
- DexCom's composite score of 62.3 is anchored by two near-top-tier sub-scores — growth at 17.5 and profitability at 17.2 — which together reflect the company's demonstrated ability to expand revenues and sustain strong margins as captured in its FY2025 10-K filing.
- The financial health and momentum sub-scores (both 16.0/20) add meaningful but not exceptional contributions, indicating a company with a reasonably clean balance sheet and positive directional operational trends that stop short of outstanding.
- The score lands at 62.3 rather than higher primarily because two full scoring dimensions — dividend and theme — contribute zero points, creating a structural ceiling that is independent of how well the core operating business performs.
Why Not Higher
- The dividend sub-score of 0.0 and theme sub-score of 0.0 together eliminate up to 40 points of scoring potential; since DexCom reinvests capital rather than returning it and did not qualify for macro theme classifications, these dimensions cannot contribute to a higher composite score under the current model.
- The financial health sub-score of 16.0, while solid, suggests that leverage ratios or interest coverage metrics derived from the 10-K are not at the highest tier, preventing that dimension from contributing its maximum possible 20 points.
Data Confidence
8 / 10
High — most data fields present
Research Summary
AI-generated analysis reflects data and conditions as of the report date shown above. Verify any specific figures through primary sources before acting on this analysis.
DexCom, Inc. is a U.S.-based medical device company specializing in continuous glucose monitoring (CGM) systems, which allow people with diabetes to track their blood glucose levels in real time without routine fingerstick testing. Its core products — the G-series and Stelo CGM platforms — are worn on the body and transmit glucose data to smartphones and compatible devices, positioning DexCom at the intersection of diabetes management and digital health. The company generates revenue primarily through sensor and transmitter sales, with a recurring consumable model that drives consistent repurchase behavior from its patient base. The model assigned DexCom a score of 62.3/100, reflecting a genuinely strong but imperfect fundamental picture derived from its FY2025 10-K filing. Growth (17.5/20) and profitability (17.2/20) are the two strongest sub-scores, indicating that the company has been delivering meaningful top-line expansion alongside improving margins and returns on assets — hallmarks of a maturing high-growth medical device business. Financial health (16.0/20) and momentum (16.0/20) are solid but not exceptional, suggesting some balance sheet leverage or interest coverage constraints and a pace of quarterly operational improvement that, while positive, has not been uniformly accelerating. The absence of a dividend score (0.0/20) is consistent with DexCom's reinvestment-focused capital allocation strategy, and the zero theme score reflects that, under the model's macro-theme exposure methodology, DXCM did not trigger qualifying theme classifications from the filing data. The central research tradeoff for DexCom is between a high-quality recurring-revenue business in a large and growing addressable market versus the lack of dividend income appeal, moderate leverage, and a score ceiling imposed by the missing theme and dividend dimensions. Researchers evaluating this name through an aggressive growth lens will find the most resonance, as the best-fit scoring profile (75.9 for aggressive growth) is materially above the all-profile composite of 62.3.
Plain English
DexCom makes small wearable sensors that diabetics use to monitor their blood sugar continuously, so they don't have to prick their fingers multiple times a day. A model score of 62.3 out of 100 means it shows strong growth and solid profits from SEC filings, but it doesn't pay dividends and carries some debt, which pulls the overall score down. The Medium risk rating reflects that DexCom is a proven business in a competitive medical device space — not a startup gamble, but also not a slow-and-steady defensive play. Researchers with an appetite for aggressive growth may find it worth deeper investigation, while income-focused researchers will likely find it a weaker fit.
Bull Case vs. Bear Case
Bull Case
- The growth sub-score of 17.5 out of 20 indicates strong year-over-year revenue and earnings expansion as reported in the FY2025 10-K, supporting the thesis that DexCom's CGM platform continues to capture a larger share of the global diabetes management market.
- A profitability sub-score of 17.2 out of 20 reflects robust net margins, operating margins, and returns on assets, suggesting that DexCom has meaningful pricing power and operational leverage as it scales its sensor manufacturing and distribution.
- The momentum sub-score of 16.0 out of 20 indicates that quarterly trends in revenue and earnings have been improving within the filing period, which supports the view that operational execution has remained consistent heading into future reporting periods.
Bear Case
- The dividend sub-score of 0.0 out of 20 confirms that DexCom pays no dividend and has no dividend streak, free cash flow payout history, or dividend growth record, making it entirely unsuitable for income-oriented research profiles.
- The financial health sub-score of 16.0 out of 20, while above average, implies some degree of balance sheet leverage or interest coverage constraints that could become more material if revenue growth decelerates or interest rate conditions tighten.
- The theme sub-score of 0.0 out of 20 means DexCom did not qualify for any of the model's macro-theme classifications from its 10-K filing, limiting its score potential under the current methodology and reducing its appeal to thematic or sector-rotation research strategies.
What Could Change the Picture
Bullish Triggers
- Acceleration in the growth sub-score — driven by further year-over-year revenue or net income expansion in future 10-K filings, particularly from international market penetration or the Stelo over-the-counter CGM platform reaching new user populations — would strengthen the research case.
- A meaningful improvement in financial health metrics, such as reduction in net leverage ratios or stronger interest coverage as shown in future filings, would push the financial health sub-score closer to 20 and lift the overall composite score.
Bearish Triggers
- A deterioration in the profitability sub-score in subsequent filings — for example, margin compression from increased competition with Abbott's Libre platform or pricing pressure from payers — would undermine the current thesis that DexCom has durable pricing power.
- A deceleration in the momentum sub-score, reflecting flattening or declining quarterly revenue and earnings trends in future regulatory filings, would signal that the strong FY2025 growth trajectory may not be sustainable and would weaken the aggressive growth research narrative.
Red Flags
- The combined absence of dividend and theme scores (both 0.0/20) accounts for a maximum possible 40 points that DexCom cannot access under the current model, structurally capping its composite score regardless of operational performance improvements.
Risk Profile
Medium RiskThe Medium risk rating reflects that DexCom operates in a competitive and innovation-intensive medical device market where regulatory risk, reimbursement changes, and technology disruption are real factors, but its established commercial scale and recurring consumable revenue model provide meaningful stability relative to earlier-stage healthcare companies.
Key Catalysts to Watch
Key factors to watch include the commercial trajectory of DexCom's Stelo OTC CGM sensor — which targets non-insulin-using diabetics and represents a significant addressable market expansion — as well as trends in gross margin and operating leverage that would be visible in future 10-K and 10-Q filings and directly impact the profitability and growth sub-scores.
This report is for educational and research purposes only. It does not constitute financial, investment, legal, or tax advice — always conduct your own due diligence before making investment decisions.